

Listing and Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-8. (Cancelled)

9. (Original) A method of killing cancer cells having a p53 mutation, said method comprising the separate, sequential or simultaneous administration to said cells of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor.

10. (Original) A method of treating cancer cells having a p53 mutation comprising the separate, sequential or simultaneous administration to a mammal in need thereof of a therapeutically effective amount of a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor.

11. (Currently amended) The method according to claim 9 ~~or claim 10~~ wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid (~~e.g. bone marrow~~) cancer.

12. (Currently amended) The method according to claim 9, ~~10 or 11~~ wherein the binding member is an antibody or a fragment thereof.

13. (Currently amended) The method according to ~~any one of claims 9 to 12~~ claim 9 wherein the death receptor is FAS.

14. (Currently amended) The method according to ~~any one of claims 9 to 13~~ claim 9 wherein the binding member is the anti-FAS antibody CH11.

15. (Currently amended) The method according to ~~any one of claims 9 to 14~~ claim 9 wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor.

16. (Currently amended) The method according to ~~any one of claims 9 to 15~~ claim 9 ~~wherein,~~ wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).

17. (Original) The method according to claim 16 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.

18. (Original) A product comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent as a combined preparation for the simultaneous, separate or sequential use in the treatment of cancer, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor, and wherein the cancer cells comprise a p53 mutation.

19. (Currently amended) A pharmaceutical composition for the treatment of cancer characterised by the presence of a p53 mutation, wherein the composition comprises a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor and (c) a pharmaceutically acceptable excipient, diluent or carrier.

20. (Currently amended) The product according to claim 18 ~~or the pharmaceutical composition according to claim 19~~ wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid ~~(e.g. bone marrow)~~ cancer.

21. (Currently amended) The product according to claim 18 ~~or claim 20 or the pharmaceutical composition according to claim 19 or claim 20~~ wherein the binding member is an antibody or a fragment thereof.

22. (Currently amended) The product according to claim 18 ~~or claim 20 or 21 or the pharmaceutical composition according to claim 19 or claim 20 or 21~~ wherein the death receptor is FAS.

23. (Currently amended) The product according to claim 18 ~~or any one of claims 20 to 22 or the pharmaceutical composition according to claim 19 or or any one of claims 20 to 22~~ wherein the binding member is the anti-FAS antibody CH11.

24. (Currently amended) The product according to claim 18 ~~or any one of claims 20 to 23 or the pharmaceutical composition according to claim 19 or or any one of claims 20 to 23~~ wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor.

25. (Currently amended) The product according to claim 18 ~~or any one of claims 20 to 24 or the pharmaceutical composition according to claim 19 or or any one of claims 20 to 24~~, wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).

26. (Currently amended) The product ~~or pharmaceutical composition~~ according to claim 25 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.

27. (Original) A kit for the treatment of a cancer characterised by the presence of a p53 mutation, said kit comprising a) a specific binding member which binds to a cell death receptor or a nucleic acid encoding said binding member and (b) a chemotherapeutic agent, wherein said chemotherapeutic agent is a topoisomerase inhibitor or a thymidylate synthase inhibitor and (c) instructions for the administration of (a) and (b) separately, sequentially or simultaneously.
28. (New) The pharmaceutical composition according to claim 19 wherein the cancer is one or more of colorectal, breast, ovarian, cervical, gastric, lung, liver, skin and myeloid cancer.
29. (New) The pharmaceutical composition according to claim 19 wherein the binding member is an antibody or a fragment thereof.
30. (New) The pharmaceutical composition according to claim 19 wherein the death receptor is FAS.
31. (New) The pharmaceutical composition according to claim 19 wherein the binding member is the anti-FAS antibody CH11.
32. (New) The pharmaceutical composition according to claim 19 wherein said chemotherapeutic agent is an antifolate thymidylate synthase inhibitor or a topoisomerase-I inhibitor.
33. (New) The pharmaceutical composition according to claim 19 wherein said chemotherapeutic agent is TDX or irinotecan (CPT-11).
34. (New) The pharmaceutical composition according to claim 25 wherein said specific binding member and chemotherapeutic agent are provided in concentrations sufficient to produce an RI of greater than 1.5.